Luigi Zuliani

Neurologist, dad, runner, interested in neuroimmunology, blues guitar and consciousness

[Mayo Florida AutoImmune Neurology Group @Mayo_AING]

I’m going - would be fab to see as many other neuroimmunologists there as possible!!

[Alberto Vogrig @Vogrig_Alberto]

ICIs can cause 2 distinct optic neuropathies 👁️
🔹 Papillitis – often with uveitis/VKH, better prognosis; ICIs may be resumed after recovery
🔹 Optic neuritis – linked to broader neurotoxicities, poorer outcomes (persistent deficits in up to 80%)
Full text
https://t.co/4CgYbT1QFd

[Luigi Zuliani @lz3103]

@LyonPNS_AE Congratulazioni Antonio 👏👏👏

[Luigi Zuliani @lz3103]

@neurotutto @Matt_Pinner Snoop doggy dog

[Elia Sechi @EliaSechi]

Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): Practical recommendations for diagnosis and management by the NINA Group @GruppoNina 🇮🇹 - Journal of Neuroimmunology https://t.co/JpSS8EFLMD

[Neurology Journal @GreenJournal]

Real-Life Evaluation of the MOGAD Diagnostic Criteria— Application Challenges and Discrepancies: https://t.co/lz1nHZ6m95

[Fabienne Brilot @FabienneBrilot]

Thank you to @MS_Australia for this great piece.
➡️ COVID-19 VAX boosters improve the longevity and cross-variant breadth of immune responses in #MS
➡️ machine-learning models predict protection or need of an extra booster.
@anneke_vdw @darshi_r @StuartTurville @syd_health

[Wallace Brownlee @DrWBRO]

1/5 The long-awaited 2024 McDonald criteria are now published! I’m proud to see that our work at @UCLIoN @UCLHresearch has helped to change the way MS is diagnosed, and that our patients will now benefit from earlier diagnosis and treatment @olgacicc
https://t.co/6jRaFnSaAT

[Valentina Damato @damato_v]

Happy to share our new work just out in JNI. We found that neuropathic pain isn't just common in CASPR2 antibody disease, but it can be the only symptom. The good news? Immunotherapy often works.

👉 https://t.co/NcrGmPnMhf

[Elia Sechi @EliaSechi]

Our new editorial is out: Optimizing Treatment of Severe Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease Attacks: It's Time to PLEX! | Neurology https://t.co/Y7qu0XnPyx @SaraMariottoMD 🇮🇹

[Carsten Finke @carstenfinke]

Our new study on @Brain1878 on atrophy patterns in IgLON5 disease led by the faboulous @SelinaYogeshwar

[Alberto Vogrig @Vogrig_Alberto]

A fantastic course organized by @RosaCortese5 and Alvino Bisecco, featuring brilliant speakers and some of the best students.

AINI Summer School
Neuroimaging in Neuroimmunology
Siena – 17–18 July 2025
The charm of the Tuscan landscape was the cherry on top!

@GruppoNina

[Raffaele Iorio @neurotutto]

A great educational event with top-tier speakers and outstanding student participation! Good job!

[Mayo Florida AutoImmune Neurology Group @Mayo_AING]

#CASPR2-#antibody diseases are provide clues to mechanisms of autoantigen-specific tolerance

Here - in @ScienceAdvances - we show how central and peripheral B cell tolerance licences pathogenic CASPR2 antibody generation.

https://t.co/lmXB9fcHBy

More below 👇🏿

[The Sumaira Foundation @TheSumairaFDN]

🗞️📰 We at TSF have some BIG news to share…

https://t.co/wazKi6kghu

[The Sumaira Foundation @TheSumairaFDN]

🌍🇮🇹💝 Esperti da tutta Italia si uniscono per augurare a tutti un felice Mese della Consapevolezza su #NMOSD e #MOGAD!

📢 Marzo è dedicato a NMOSD, mentre aprile sarà il mese di MOGAD. Un’occasione per sensibilizzare, supportare la ricerca e dare voce ai pazienti.

[Matteo Gastaldi @MGastaldi85]

https://t.co/ZJHaeghpzv

Proud to share @StefanoMascio91 latest work on PLP1 antibodies in demyelinating diseases. PLP1 abs are mainly found in patients with non MS diseases with combined central and peripheral demyelination, but also in rare seronegative NMOSD

[Brain @Brain1878]

The benefits of early initiation of disease-modifying therapy in MS are well-established, but when & how to de-escalate treatment remains unclear. Androdias et al. summarise findings from an ECTRIMS workshop on this topic and propose practical guidelines. https://t.co/J35eUKZQ6H

[Alberto Vogrig @Vogrig_Alberto]

Great piece by @tompollak —worth reading. While a small minority of patients with psychiatric disorders (rarely isolated) have an autoimmune basis like AE, most do not. Using immunosuppressants outside Ab-positive AE is risky and often ineffective
https://t.co/qWPGm3Nqmy

[Eoin Flanagan @EoinFlanagan14]

Delighted to share @dinoto_ale et al study on the rare cerebellar attacks in #NMOSD attacks: ➡️ Often coexist with brainstem attacks ➡️ MRIs with peduncle or dentate nucleus lesions ➡️ Should be incorporated in upcoming 2025 #NMOSD diagnostic criteria 👇 https://t.co/rvTM7t5xmC